blonanserin has been researched along with Anochlesia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A | 1 |
Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A | 1 |
2 other study(ies) available for blonanserin and Anochlesia
Article | Year |
---|---|
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines | 2015 |
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Mice, Inbred Strains; Nucleus Accumbens; Piperazines; Piperidines; Proto-Oncogene Proteins c-fos; Pyridines; Serotonin 5-HT2 Receptor Antagonists | 2010 |